Basic Information
| LncRNA/CircRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | Microarray, qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | HCC tissues, cell lines (HepG2, Hep3B, SNU-423 cells. Huh7, L02, SMMC-7721, MHCC-97H) |
| Expression Pattern | up-regulated |
| Function Description | Here, based on the increased level of LINC00152 in HCC tissues, we found that LINC00152 could promote cell proliferation in vitro and tumor growth in vivo. Furthermore, microarray-based analysis indicated that LINC00152 could activate the mechanistic target of rapamycin(mTOR) pathway by binding to the promoter of EpCAM through a cis-regulation, as confirmed by Gal4-??/BoxB reporter system. |
| Pubmed ID | 26540343 |
| Year | 2015 |
| Title | LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. |
External Links
| Links for LINC00152 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |